Incorporating genetics into the identification and treatment of XXXX .

@entity1 @entity2416 @entity3794 @entity16058
BACKGROUND: @entity2416 , the most common form of @entity16058 , is characterized by progressive, irreversible scarring of the lung parenchyma. @entity2416 has a poor prognosis, and there are no medical therapies available that have been shown to improve survival. It is usually sporadic, but there is evidence of familial clustering of @entity3794 , suggesting a genetic basis for this disease. More recently, studies have confirmed that specific genetic variants are associated with both familial and sporadic forms of @entity3794 . DISCUSSION: Although there are common and rare genetic variants that have been associated with the risk of developing @entity3794 , the genotyping of @entity1 is not a generally accepted strategy. Better understanding of the interplay between genetic risk and environmental exposure is likely needed to inform both treatment and disease prevention. Several identified disease-associated genetic variants have implications for disease progression and survival, but systematic studies of known genetic variants and their influence on therapeutic efficacy are lacking. Future investigations should focus on understanding phenotypic differences between @entity1 carrying different risk alleles, and clinical studies should be designed to control for the influence of different genetic risk variants on @entity1 outcomes. Inherited genetic factors play a significant role in the risk of developing @entity3794 . Future studies will be needed to characterize @entity1 phenotypes and to understand how these genetic factors will influence clinical decision-making for both diagnosis and treatment of @entity2416 .
